Osborne Park-based Solbec Pharmaceuticals Ltd has had a small win, with the United States Food and Drug Administration allowing the use of its Coramsine cancer treatment under a Physician's Investigational New Drug application.
Shares in Fremantle company Solbec Pharmaceuticals Ltd have soared on news it has been awarded a US patent it considers a strong indicator of further IP portfolio growth.
Perth biotechology firm Solbec Pharmaceuticals Ltd is seeking to remove a big "overhang" of options, offering holders of the instruments shares in the company to reduce the almost 150 million options on issue.
Solbec Pharmaceuticals Limited has announced its lead anti-cancer compound Coramsine has received orphan drug designation from the US Food and Drug Administration.
SOLBEC Pharmaceuticals has announced that its safety trial of Coamsine in the treatment of psoriasis has finished successfully and ahead of schedule.This clinical trial, which was designed to demonstr
A treatment developed by Western Australian biotechnology company Solbec Pharmaceuticals has led to total remission of mesothelioma in mice.The results come from trials conducted by the Tumour Immunol
SOME patients taking part in phase 1 trials of Solbec Pharmaceuticals anti-cancer drug SBP002 have asked to continue taking the drug.Solbec has announced that the drug had proved successful in reducin
Solbec Pharmaceuticals has received a positive international preliminary examination report on its manufacturing patent application for the method of separation of the key ingredient in its cancer fig
A MINER turned biotechnical player making an anti-cancer drug from a declared weed is three months away from getting the first results from clinical trials relating to its cancer drug.
SOLBEC Pharmaceuticals has agreed to sell its interest in the Lawley Pharmaceuticals Joint Venture, following a comprehensive review of the hormone replacement therapy project.
Solbec Pharmaceuticals Ltd
13/3/03
M Ruane decreased its relevant interest from 25,372,010 ordinary shares (17.00%) to 8,160,827 ordinary shares (5.12%)
Solbec Pharmaceuticals is continuing its investigation into the behaviour of its lead cancer product, developed from elements found in weed colloquially known as ‘Devil’s Apple’.
